From: Breast Cancer Treatment (PDQ®)
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Table 7. Systemic Treatment for Early Breast Cancer by Subtypea
| Subtype | Treatment Options | Comments |
|---|---|---|
| Luminal A–like | ||
| – Hormone receptor–positive | Endocrine therapy alone in most cases | Consider chemotherapy if: |
| – HER2-negative | – High tumor burden (≥4 LNs, T3 or higher) | |
| – PR >20% | ||
| – Ki67 low | – Grade 3 | |
| Luminal B–like | ||
| – Hormone receptor–positive | Endocrine therapy plus chemotherapy in most cases | |
| – HER2-negative | ||
| – Either Ki67 high or PR low | ||
| HER2-positive | Chemotherapy plus anti-HER2 therapy | Use endocrine therapy, if also hormone receptor–positive |
| May consider omitting chemotherapy plus anti-HER2, for small node-negative tumors | ||
| Triple-negative | Chemotherapy | May consider omitting CT, for small node-negative tumors |
CT = chemotherapy; ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; LN = lymph node; PR = progesterone receptor.
aModified from Senkus et al.[82]